In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that ...

In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that ...

Treatment options for patients with moderately to severely active Crohn's disease have expanded in the past decade, with ...

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis Published. Oct 10, 2024 8:00am EDT.

The guselkumab group received 100-mg injections at week 0, week 4, and then every 8 weeks through week 44; the placebo group received injections at weeks 0, 4, 12, and 20, followed by 100 mg of ...

Guselkumab results in higher enthesitis resolutions rates at week 24, with maintenance of those higher rates through 1 year, in patients with PsA, according to data derived from McGonagle D, ...

TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission.

The monoclonal antibody guselkumab (Tremfya), which binds the interleukin (IL)-23 p19 subunit, was effective for psoriatic arthritis in two large clinical trials, providing comprehensive benefits ...

In a major advance for patients with Crohn’s disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of action that is new to ...